Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Azurrx Biopharma Inc (NQ: AZRX )

0.8698 USD +0.0856 (+10.92%)
Official Closing Price Updated: 7:59 PM EDT, Apr 20, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about Azurrx Biopharma Inc

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
3 Reopening Penny Stocks to Watch in April 2021
Tags Market News
From Penny Stocks to Buy, Picks, News and Information | PennyStocks.com - Feed
BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Shareholder Letter Outlines Program Highlights, Provides Business Update
From InvestorBrandNetwork
AzurRx BioPharma CEO Issues Letter to Shareholders
From GlobeNewswire News Releases
BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Enters Agreement for Upcoming Phase 1b/2a Clinical Trial
From InvestorBrandNetwork
AzurRx BioPharma Engages PPD to Manage Clinical Trial for Niclosamide as Treatment for Grade 1 Immune Checkpoint Inhibitor-Associated Colitis
Phase 1b/2a Study Expected to Begin In 2Q 2021 
From GlobeNewswire News Releases
Nonhospitalized Long-Haul Coronavirus Patients Susceptible to Cognitive Dysfunction
From InvestorBrandNetwork
BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Initiates Phase 2 RESERVOIR Trial for Treatment of COVID-19 GI Infections
From InvestorBrandNetwork
AzurRx BioPharma To Test Formulated Niclosamide In COVID-19-Related Gastrointestinal Infections
AzurRx BioPharma Inc(NASDAQ:AZRX)has initiatedPhase 2 RESERVOIR trial evaluating oral formulation of ... 
Tags Benzinga AZRX Market News
From Benzinga
AzurRx BioPharma Initiates Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections
From GlobeNewswire News Releases
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Chembio Diagnostics (NASDAQ:CEMI) shares rose 47.29% to $5.17 during Monday's pre-market session. The market ... 
Tags AMTI OCUP Top Gainers
From Benzinga
Today’s Biggest Pre-Market Movers: 10 Top Stock Gainers and Losers on Monday Morning
<p><a rel="nofollow" href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice & Trading Tips</a></p> <p>The Easter weekend is over and it's time to prepare for a busy day of... 
Tags NVVE AZRX NNOX
From InvestorPlace
48 Biggest Movers From Thursday
Gainers AeroCentury Corp. (NYSE: ACY) jumped 173.2% to close at $9.70 on Thursday. The company recently reported that it filed a ... 
Tags BTAI ZH GES
From Benzinga
Mid-Afternoon Market Update: Nasdaq Jumps Over 200 Points; AzurRx BioPharma Shares Slide
Toward the end of trading Thursday, the Dow traded up 0.49% to 33,143.12 while the NASDAQ rose 1.56% to 13,454.06. The S&P also ... 
Tags LTRPB Global Benzinga
From Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Applied Molecular (NASDAQ:AMTI) shares rose 31.56% to $57.9 during Thursday's regular session. Trading ... 
Tags EBS CTIC Benzinga
From Benzinga
BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Key Results from Phase 2b OPTION 2 Clinical Trial
From InvestorBrandNetwork
Mid-Day Market Update: Crude Oil Rises Over 1%; BioXcel Therapeutics Shares Plummet
Midway through trading Thursday, the Dow traded up 0.25% to 33,064.19 while the NASDAQ rose 1.71% to 13,473.41. The S&P also rose, ... 
Tags UPC News KMX
From Benzinga
42 Stocks Moving In Thursday's Mid-Day Session
Gainers Liberty TripAdvisor Holdings, Inc. (NASDAQ: LTRPB) shares jumped 143.4% to $90.05 after climbing 42% on ... 
Tags AMTI UTHR FTFT
From Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Sonoma Pharmaceuticals (NASDAQ:SNOA) shares rose 27.33% to $9.46 during Thursday's pre-market session. The ... 
Tags CTIC JAGX EBS
From Benzinga
31 Stocks Moving in Thursday's Pre-Market Session
Gainers Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) rose 44.4% to $10.73 in pre-market trading after the company, and EMC Pharma, ... 
Tags GES BTAI CVV
From Benzinga
AzurRx's Stock Falls After MS1819 For Pancreatic Insufficiency Flunks Mid-Stage Study
AzurRx BioPharma Inc(NASDAQ:AZRX)reported topline resultsfrom its Phase 2b OPTION 2 trial evaluating MS1819 ... 
Tags FDA Phase 2 Trial Health Care
From Benzinga
12 Stocks Moving In Wednesday's After-Hours Session
Gainers Micron Technology (NASDAQ: MU) shares are trading higher after the company reported better-than-expected Q2 EPS and sales ... 
Tags AZRX After/Hours Center Movers
From Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers AzurRx BioPharma (NASDAQ:AZRX) stock rose 17.16% to $1.57 during Wednesday's after-market session. This security traded ... 
Tags Market News PRPH ADTX
From Benzinga
AzurRx BioPharma Provides Key Takeaways from Phase 2b OPTION 2 Clinical Trial Topline Results Conference Call
From GlobeNewswire News Releases
AzurRx BioPharma to Report Topline Data from Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis
AzurRx to Host Conference Call and Live Audio Webcast Today, Wednesday, March 31, 2021 at 4:30 p.m. ET 
From GlobeNewswire News Releases
Thinking about buying stock in CASI Pharmaceuticals, Windtree Therapeutics, ChargePoint Holdings, FreightCar America, or AzurRx BioPharma?
InvestorsObserver issues critical PriceWatch Alerts for CASI, WINT, CHPT, RAIL, and AZRX. 
From PR Newswire
Research Finds That Covid-19 Infection Increases Chance of Stroke Among Patients
From InvestorBrandNetwork
4 Biotech Penny Stocks To Watch This Week With Bullish Analyst Ratings
Tags Market News
From Penny Stocks to Buy, Picks, News and Information | PennyStocks.com - Feed
The Week Ahead In Biotech (March 28-April 3): Acadia's Dementia Drug Update, Clinical Readouts, Few Earnings In Holiday-Shortened Week
Biotech stocks reversed course and ended lower in the week ended March 26, drawing inspiration from the broader market weakness. The ... 
Tags FDA BLUE BLCM
From Benzinga
BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Completes Enrollment in Phase 2 MS1819-PERT Combination Clinical Trial
From InvestorBrandNetwork
AzurRx BioPharma Announces Completion of Enrollment in Phase 2 Clinical Trial of MS1819 in Combination with PERT in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficie
Top-line data expected in Q2 2021 
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.